Navigation Links
BioReliance Appoints Executive Chairman to be Interim CEO and Announces Recent Senior Executive Additions
Date:10/29/2007

ROCKVILLE, Md., Oct. 29 /PRNewswire/ -- BioReliance Corporation today appointed its Executive Chairman, Charles C. Harwood, Jr., to the additional post of Interim CEO, following the announced resignation of Tim Derrington from the CEO position. In addition, BioReliance announced that three senior executives have joined the company since June: David E. Onions, Ph.D., as Chief Scientific Officer, David S. Walker as Chief Financial Officer, and Darryl L. Goss as Vice President of Global Process Excellence.

BioReliance is a portfolio company of Avista Capital Partners and was purchased in April 2007 from Invitrogen Corporation. Charles Harwood comments, "While Tim Derrington's personal decision to leave BioReliance was not anticipated at the time of the acquisition, the Board does not believe it will affect the timetable for strengthening the senior executive team and setting a clear course for BioReliance as a stand-alone company."

In addition to serving as Executive Chairman of BioReliance, Mr. Harwood serves on the boards of several other healthcare companies, including ATCC and RadPharm, Inc., and recently formalized a relationship with Avista to support their healthcare team as a Healthcare Industry Advisor. From 2002 to 2006, Mr. Harwood served as President and CEO of Focus Diagnostics, Inc., a specialty diagnostics company offering advanced laboratory testing services and diagnostic products. Previously, from 1993 to 2001, Mr. Harwood held several positions, including Chief Financial Officer and SVP of Venture Development, at Covance, Inc., one of the largest drug development services companies. Mr. Harwood began his healthcare career in the medical equipment field working for the Medical Products Group of Hewlett-Packard Company. He received an MBA from Harvard Business School and a Bachelor of Arts from Stanford University.

David Onions is the Chief Scientific Officer and a member of the Board of BioReliance. He was formerly Chief Medical Officer of Invitrogen and before that Director of the Leukaemia Research Fund's Virus Centre and Professor of Veterinary Virology at the University of Glasgow. Dr. Onions was a founding director of Q-One Biotech which was acquired by BioReliance in 2003. He is a member, or former member, of several advisory groups including the FDA's Xenotransplantation Advisory Committee and the World Health Organisation's Expert Advisory Panel on Biological Standardization. Dr. Onions is a Fellow of the Royal Society of Edinburgh, Fellow of the Academy of Medical Sciences, and a Fellow of the Royal Society of Arts.

David Walker serves as the Chief Financial Officer of BioReliance. Previously, Mr. Walker was the CFO of American Type Culture Collection, or ATCC. From 2003 to 2006, Mr. Walker was the VP and CFO of Focus Diagnostics. He served as SVP and CFO of Restoragen, Inc. from 2000 to 2003. Prior to 2000, Mr. Walker held various senior finance positions with Arbor Acres, Inc., Fisons plc, and The Boots Company, plc. Mr. Walker graduated from Nottingham Trent University in Nottingham, England, with a degree in Accounting and Finance and is a qualified member of the Chartered Institute of Management Accountants in England.

Darryl Goss has joined BioReliance as the VP of Global Process Excellence. Prior to joining BioReliance, Mr. Goss was SVP and Chief Operating Officer of Esoterix, Inc. following its acquisition by LabCorp. From 2000 to 2005, he held a variety of other senior executive roles at Esoterix including SVP of Business Operations and Chief Information Officer. From 1993 to 2000, Mr. Goss worked at Covance Central Laboratory Services, Inc., serving in such roles as VP of Information Technology & Services. Prior to 1993, he held various information technology and business development positions with Smith Kline Beecham Clinical Laboratories, Guidance Opportunity, Inc., Beatrice Hunt-Wesson and IBM. Mr. Goss has a Masters of Business Administration from the University of Chicago and completed post-graduate work in Advanced Management from Oxford University in Oxford, England. In addition, Mr. Goss graduated from the University of California Davis with a Bachelor of Arts.

About BioReliance

BioReliance Corporation is a leading contract services organization, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing and lab animal health diagnostics for the biopharmaceutical and pharmaceutical industries. BioReliance has its primary facilities in Rockville, Maryland; Glasgow, Scotland; and Stirling, Scotland. Headquartered in Rockville, Maryland, BioReliance employs over 700 people globally. For more information, visit http://www.bioreliance.com.

Contact:

David Walker, BioReliance, 301-610-2866, david.walker@bioreliance.com


'/>"/>
SOURCE BioReliance Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Where Burnt Out Executives De-stress in Natures Lap
2. Asian Business Executives Urged to Be Eco-friendly
3. BMA Welcomes Scottish Executives Move to Raise the Purchase Age of Cigarettes
4. Bruce Vladeck Will Hold Fort (interim) of UMDNJ
5. Interim WHO Chief Confirms No radical changes in WHO
6. Interim OPD saves the day for patients
7. PM announces a new health care order for India
8. Ramdoss Announces Introduction of RCH-II
9. Britain Announces Third Transfusion Related Mad Cow Case
10. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
11. Tibet Announces the Dalai Lama’s Tour of South Americ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... and women’s professional squash, announced it has enlisted New York City-based sports and ... agency will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), ...
(Date:3/29/2017)... ... 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, & ... and college students who have participated in the program every summer. The 2017 ... accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I ...
(Date:3/29/2017)... ... 29, 2017 , ... AngioGenesis Labs sold 300 bottles of ... Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while doing a ... over the counter heart healthy drink, can reduce Arterial Plaque, Lower Blood Pressure, ...
(Date:3/29/2017)... ... , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is ... or without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. ... patients receive early treatment, they may achieve straight teeth with less treatment in their ...
(Date:3/29/2017)... ... 2017 , ... Curio Wellness , a premium medical cannabis brand and ... executive management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... TREE, Colo. , March 29, 2017  Zynex (OTCQB: ... manufacture and sale of non-invasive medical devices for pain ... today that it will host the Company,s 2016 full-year ... a.m. Eastern Time.) The Company expects to ... 31, 2017. ...
(Date:3/29/2017)... , March 29, 2017 According to a new ... Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, ... 2021" published by MarketsandMarkets, the market is expected to reach USD 1,215.4 ... of 6.5% from 2016 to 2021. Continue ... ...
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care ... a new PhRMA report on patient out-of-pocket spending: ... Medicare and Medicaid Services (CMS), the average amount spent ... 13% of drug spending in 2016, down from 23% ... a pricing problem, not a coverage problem. Health plans ...
Breaking Medicine Technology: